Date post: | 06-Apr-2015 |
Category: |
Documents |
Upload: | indonesian-journal-of-cancer |
View: | 42 times |
Download: | 3 times |
Hudi Hastowo
Badan Tenaga Nuklir Nasional-BATAN 5 November 2009
Role of BATAN in Establishing Nuclear Oncology in Indonesia
BATAN has the following functions :
l To assess and prepare the national policy in the field of research, development, and the beneficial uses of nuclear energy:
l Food, energy, health, etc
l To support and foster activities of government institutions in the field of research, development and beneficial uses of nuclear energy,
l Liaison officer to the international institution dealing with nuclear activities: IAEA, FNCA, others
l Cancer kills 7 million people each year l 25 million live with cancer; over 10 million new cases this
year, more than half in developing countries and increasingl By 2020, cancer could kill over 10 million, while new cases
could rise to 16 million per year unless we actl Radiation and nuclear oncology is an essential and integral
component of cancer carel In spite of assistance programs, developing countries not
able to deal with this epidemic todayl More than 2 million lives can be saved by 2020 if
appropriate measures are put in place to prevent, detect early, diagnose, and cure
The Burden of Cancer
Massoud Samiei, IAEA
l Program of Action for Cancer Therapy (PACT) is the IAEA’s response to the cancer challenge in developing countries
• The long-term objective of PACT is:
PACT: IAEA’s Response …
Sustainable National Capacity for Cancer Care
l Build sustainable national cancer care infrastructure and capacity towards eventual self-sufficiency through South-South and North-South partnerships
l Systematically plan and build capacity to diagnose and treat all patients with radiosensitive cancers
l Focus on eliminating all cancer morbidity and mortality from unmet treatment needs among patients for whom radiotherapy is most effective
l Deploy consistent and predictable resources and processes including investments from private donors to meet these objectives over a 5 to 10 year strategy
The Vision for PACT
Massoud Samiei, IAEA
PACT is being operationalised using specific mechanisms such as imPACT (integrated missions of PACT)
l Assist governments to review, analyse and formulate National Cancer Strategies and Action Plans for capacity building from prevention through palliation
l Enable institutions to build and develop human resources and plans for capacity in radiation and nuclear oncology
The imPACT Review will:
The results of imPACT will enable governments to:
l Work with partnersl Focus on centres of competence/reference to deliver
quality cancer carel Raise public awareness of cancer prevention,
diagnosis, and therapyl Apply best practices, expand and continue
professional developmentMassoud Samiei, IAEA
IAEA Ministry of Research & Technology
Ministry of Health
DG of Medical Care, Ministry of Health
DG of Disease Control & Environmental Health,
Ministry of Health
National Nuclear Energy Agency
(BATAN)
Dharmais Cancer Hospital, National Cancer Center
National Cancer Control Program• Prevention• Early detection • Diagnosis• Treatment
PACT• Cancer Diagnosis• Cancer Treatment
PACT Fundamentals• National Cancer Control Programs:
• Radiation Medicine and the role of the BATAN and the IAEA
Ø PreventionØ Early DetectionØ Diagnosis and TreatmentØ Palliative Care
* Radiation Medicine includes both radiotherapy (or radiation oncology) and diagnostic imaging involving the safe use of ionizing radiation and nuclear medicine procedures.
BATAN’s Role for PACT/Nuclear Oncology:
• Carry out R&D on radiopharmaceuticals, RIA/IRMA Kits, and brachytherapy sealed sources for PACT
• Encourage national companies, such as PT Kimia Farma, PT Batan Technology to produce and distribute products for PACT developed by BATAN
• Provide services to nuclear instruments associated with PACT
Radiopharmaceuticals developed by BATAN for Nuclear Oncology:l PET and SPECT radiopharmaceuticals, such as 18FDG,
18FLT, 123I-MIBG, 99mTc-HYNIC Octreotide, 99mTc-HYNIC-Folate, etc.
l Therapeutic radiopharmaceuticals:
l PZC-Based 188W/188Re Therapeutic Generator
- 153Sm-EDTMP- 186Re-HEDP- 131I-MIBG - 131I-Lipiodol - 177Lu-DOTA-Nimotuzumab- 177Lu-DOTA-Trastuzumab Radioimmunotherapy
RIA Kits developed by BATAN for Nuclear Oncology:
• IRMA Kit CA 125 for in vitro diagnosis of ovarium cancer
• IRMA Kit CA 15.3 for in vitro diagnosis of breast cancer
Sealed Sources developed by BATAN for Nuclear Oncology:
l125I Seed sealed sources for seed brachytherapy of prostate cancer
l192Ir needle sealed sources for HDR/LDR brachytherapyfor cervics cancer, etc.
BATAN’s Facility for Producing Radionuclide of 125I
BATAN’s Laser Welder for preparing 125I seed and 192Ir needle sealed-sources
125I seed sealed-sources
Brachytherapy of Prostate Cancer using 125I seeds
Program Action BATAN’s Contribution
• Early Detection• Develop RIA/IRMA Kits, PET and
SPECT radiopharmaceuticals as required by Hospitals involved in PACT
• Diagnosis • Develop PET and SPECT radiopharmaceuticals as required by Hospitals involved in PACT
• Treatment or Therapy
• Develop sealed sources (needle, seed)for HDR and LDR Brachytherapy, CND Brachytherapy, Targeted Therapeutic Radiopharmaceuticals
• Palliative Care • Develop simple and targeted therapeutic radiopharmaceuticals
Summary
• BATAN will actively involve to support PACT through the R&D programs in the health field.
• BATAN will encourage a close relationship and communication between BATAN’s Centers with hospitals/medical doctors to develop radiopharmaceuticals/RIA and IRMA Kits, sealed sources for brachytherapy suitable for local condition.
THANK YOU